Learn
Research-backed guides on CBD pharmacology, medication safety, and condition-specific evidence. Every article cites primary literature โ PubMed where available.
GLP-1 medications
Semaglutide and tirzepatide cause real changes in joint loading and lean mass. These guides cite the primary literature โ including a widely-cited RCT that was retracted โ and say plainly where the evidence runs out.
CBD inhibits CYP3A4, CYP2C9, CYP2C19, CYP2D6, and UGT enzymes, the same pathways that clear most prescription medications. Per-drug evidence, severity ratings, and prescriber questions.
Warfarin
INR monitoring required
Benzodiazepines
Geffrey 2015: clobazam +60%, N-CLB +500%
SSRIs
Anderson 2022: CYP2D6 pharmacogenomics matter
Statins
CYP3A4, simvastatin / atorvastatin highest risk
Blood pressure medications
CYP3A4 + direct BP-lowering signal (Jadoon 2017)
Plaquenil (hydroxychloroquine)
CYP2D6 + CYP3A4 dual pathway
NSAIDs
OTC occasional: low risk; chronic Rx: discuss with prescriber
Levothyroxine
Absorption timing; TSH monitoring on long-term CBD
Gabapentin
Not CYP-mediated; additive sedation is the concern
Tylenol (acetaminophen)
UGT overlap + AM404; chronic high-dose use warrants awareness
Prednisone
23 years on steroids: the CYP3A4 picture and what tapering actually involved
Methotrexate
The DMARD most RA patients start on; what to watch beyond the CYP question
Blood thinners (warfarin, DOACs, aspirin)
The answer differs by drug class, not just by dose
Celebrex (celecoxib)
CYP2C9 pathway; NSAID-to-CBD transition considerations
Meloxicam (Mobic)
Dual CYP2C9 + CYP3A4 pathway
Biologics (Rituximab, TNF inhibitors)
Counterintuitively low pharmacokinetic interaction; 7 years of infusions
CYP450 mechanism explainer
How enzyme inhibition works, plain English
What the research says, and doesn't say, about CBD for specific autoimmune and inflammatory conditions. Honest evidence framing; no therapeutic claims.
Hashimoto's thyroiditis
No clinical trials for Hashimoto + CBD; ECS mechanism and safety context
Psoriatic arthritis
Vela 2022 RCT: null result for PsA specifically; honest framing
Ankylosing spondylitis
No AS-specific CBD trial; IL-17/IL-23 axis + Fitzcharles 2016 survey context
Hip osteoarthritis
Pramhas 2023 was knee-specific; topical CBD cannot reach hip joint
How-to guides
Practical protocols for using CBD safely and effectively.
CBD and joint pain: evidence by condition, topical vs oral, medication safety
Pillar hub, Pramhas 2023 RCT anchor; Vela 2022 null; 6 condition evidence table
Pain patches compared: lidocaine, capsaicin, NSAID, and CBD
Which patch type suits which pain; OTC vs prescription; what each active actually does
Inflammaging and CBD: the Franceschi framework and what the evidence supports
Franceschi 2018 framework; NF-ฮบB/Nrf2/CB2; honest 'no human RCT' disclosure
CBD and inflammation: the mechanism explainer
NF-ฮบB, CB2, Th1/Th17, FAAH, preclinical strong, human evidence condition-specific
CBD and chronic pain: what the evidence actually shows
Pain type framework: nociceptive, neuropathic, nociplastic, Pramhas 2023 + Mucke 2018
CBD science & dosing: how it works, bioavailability, and dosing
ECS, FAAH, inverted-U dose-response (Linares 2019), food effect (Birnbaum 2019 4โ5ร)
CBD dosing for autoimmune conditions
Start at 10mg, not 25mg, drug interactions come first
CBD for sleep and stress: pillar hub
Shannon 2019 + Bergamaschi 2011; 5-HT1A not GABA-A; cortisol/HPA axis bridge
CBD and sleep
Shannon 2019 n=72: continuity over initiation; not a sedative
CBD and anxiety
Bergamaschi 2011 RCT + Shannon 2019: acute model stronger than chronic GAD
CBD titration protocol
General start low, go slow protocol, Linares 2019
How to read a CBD certificate of analysis
Potency, pesticides, heavy metals, and what to look for
CBD for masters athletes
Recovery, inflammation, and WADA compliance